美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Kurv Yield Premium Strategy Tesla (TSLA) ETF

19.95

+0.67003.48%

盤後：19.950.00000.00%17:42 EDT

成交量：6.23萬

成交額：124.39萬

市值：2,054.85萬

市盈率：- -

高：20.27

開：19.61

低：19.61

收：19.28

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

和鉑醫藥公佈2024年度業績

【華海藥業：下屬子公司獲HB0056注射液臨牀試驗許可】金融界2月21日消息，近日，華海藥業下屬子公司上海華奧泰生物藥業股份有限公司和華博生物醫藥技術（上海）有限公司收到國家藥品監督管理局核准簽發的HB0056注射液的《藥物臨牀試驗批准通知書》。該藥物適應症為哮喘，劑型為注射劑。2024年10月，子公司獲新西蘭相關部門批准開展I期臨牀試驗；2025年1月，獲美國食品藥品監督管理局批准在美國開展臨牀試驗；2024年12月4日向國家藥監局提交臨牀試驗申請並於近日獲批。公司在HB0056項目上已合計投入研發費用約6,367萬元。HB0056是雙特異性抗體，能靶向TSLP和IL-11。2022年國內哮喘藥物市場規模達38億美元。但醫藥產品研發存風險。

【和鉑醫藥-B(02142.HK)：針對治療慢性阻塞性肺病的HBM9378/SKB378獲批NMPA的IND許可】和鉑醫藥-B(02142.HK)發佈公告，集團針對胸腺基質淋巴細胞生成素(TSLP)的全人源單克隆抗體HBM9378/SKB378(亦稱為WIN378)已獲得中國國家藥品監督管理局(NMPA)藥品審評中心的新藥研究申請(IND)批件，以開展治療慢性阻塞性肺病(COPD)的臨牀試驗。

和鉑醫藥HBM9378/SKB378治療慢性阻塞性肺疾病的臨牀試驗申請獲中國國家藥品監督管理局批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TSLP"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TSLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":19.95,"timestamp":1746820800000,"preClose":19.28,"halted":0,"volume":62340,"hourTrading":{"tag":"盘后","latestPrice":19.95,"preClose":19.95,"latestTime":"17:42 EDT","volume":22,"amount":444.2875,"timestamp":1746826945059},"delay":0,"floatShares":1030000,"shares":1030000,"eps":0,"marketStatus":"休市中","change":0.67,"latestTime":"05-09 16:00:00 EDT","open":19.61,"high":20.2678,"low":19.61,"amount":1243938.9741,"amplitude":0.034118,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":19.28,"sharesOutstanding":1030000,"nav":19.33,"aum":19909900,"dividendRate":0.445614,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.55,"preClose":19.28,"latestTime":"08:30 EDT","volume":52,"amount":1018.6000760000001,"timestamp":1746793848244},"postHourTrading":{"tag":"盘后","latestPrice":19.95,"preClose":19.95,"latestTime":"17:42 EDT","volume":22,"amount":444.2875,"timestamp":1746826945059},"volumeRatio":1.802526,"impliedVol":0.418,"impliedVolPercentile":0.8},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","floatShares":1030000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.802526,"shares":1030000,"dividePrice":8.89,"high":20.2678,"amplitude":0.034118,"preClose":19.28,"low":19.61,"week52Low":15.36,"pbRate":"--","week52High":34.2895,"institutionHeld":0,"latestPrice":19.95,"eps":0,"divideRate":0.445614,"volume":62340,"delay":0,"ttmEps":0,"open":19.61,"prevYearClose":30.27,"prevWeekClose":19.9339,"prevMonthClose":19.63,"prevQuarterClose":18.48,"fiveDayClose":19.9339,"twentyDayClose":17.53,"sixtyDayClose":24.54},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TSLP\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TSLP\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523948329","title":"和鉑醫藥公佈2024年度業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948329","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948329?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743415980,"startTime":"0","endTime":"0","summary":"中国上海、美国马萨诸塞州剑桥和荷兰鹿特丹2025年3月31日 /美通社/ -- 和铂医药，一家专注于免疫性疾病及肿瘤领域创新药研发的全球生物医药公司，今日公布其2024年度业绩。同时，和铂医药保持稳健的财务状况，截至 2024 年 12 月 31 日，公司现金及现金等价物约12亿元人民币，为后续发展奠定了坚实的财务基础。公司于2022年2月获得NMPA对HBM9378治疗中重度哮喘的IND批准，随后在中国完成对健康受试者的I期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4653322_ZH53322_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["02142","IE0031619046.USD","LU1093756168.USD","LU1863844665.USD","GB00BDT5M118.USD","LU1506573853.SGD","LU1880398471.USD","LU2463526074.USD","LU0708994859.HKD","LU0868494617.USD","LU1880398554.USD","LU0942090050.USD","LU2360108059.USD","LU1267930573.SGD","LU0128525929.USD","BK4011","LU0029864427.USD","LU2092937221.SGD","LU0868494708.USD","CRH","LU1291149836.SGD","IE00B66KJ199.SGD","LU1804176565.USD","LU2298321311.HKD","IE00B19Z4B17.USD","LU2041044095.USD","LU2265009873.SGD","BK1583","LU1035777561.USD","SD","BK1574","LU1019634622.SGD","LU0314106906.USD","BK4213","BK4006","LU0238689110.USD","CRS","IE00B7SZL793.SGD","TSLP","LU1863844749.USD","BK1161","LU1039938227.USD","LU1093756325.SGD","LU2065731478.USD","LU0310800379.SGD","LU1019632923.USD"],"gpt_icon":1},{"id":"2513043254","title":"【華海藥業：下屬子公司獲HB0056注射液臨牀試驗許可】金融界2月21日消息，近日，華海藥業下屬子公司上海華奧泰生物藥業股份有限公司和華博生物醫藥技術（上海）有限公司收到國家藥品監督管理局核准簽發的HB0056注射液的《藥物臨牀試驗批准通知書》。該藥物適應症為哮喘，劑型為注射劑。2024年10月，子公司獲新西蘭相關部門批准開展I期臨牀試驗；2025年1月，獲美國食品藥品監督管理局批准在美國開展臨牀試驗；2024年12月4日向國家藥監局提交臨牀試驗申請並於近日獲批。公司在HB0056項目上已合計投入研發費用約6,367萬元。HB0056是雙特異性抗體，能靶向TSLP和IL-11。2022年國內哮喘藥物市場規模達38億美元。但醫藥產品研發存風險。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513043254","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513043254?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 17:27","pubTimestamp":1740130054,"startTime":"0","endTime":"0","summary":"金融界2月21日消息，近日，华海药业下属子公司上海华奥泰生物药业股份有限公司和华博生物医药技术（上海）有限公司收到国家药品监督管理局核准签发的HB0056注射液的《药物临床试验批准通知书》。该药物适应症为哮喘，剂型为注射剂。2024年10月，子公司获新西兰相关部门批准开展I期临床试验；2025年1月，获美国食品药品监督管理局批准在美国开展临床试验；2024年12月4日向国家药监局提交临床试验申请并于近日获批。公司在HB0056项目上已合计投入研发费用约6,367万元。HB0056是双特异性抗体，能靶向TSLP和IL-11。2022年国内哮喘药物市场规模达38亿美元。但医药产品研发存风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21172748309954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600521","03347","BK1574","BK0070","TSLP","09939","BK1141","161726","BK0239","BK1161","BK0012","BK1583","BK0188","688606","399441","BK0028","BK0185","BK1515","159938","BK0201","BK1576"],"gpt_icon":0},{"id":"2509668428","title":"【和鉑醫藥-B(02142.HK)：針對治療慢性阻塞性肺病的HBM9378/SKB378獲批NMPA的IND許可】和鉑醫藥-B(02142.HK)發佈公告，集團針對胸腺基質淋巴細胞生成素(TSLP)的全人源單克隆抗體HBM9378/SKB378(亦稱為WIN378)已獲得中國國家藥品監督管理局(NMPA)藥品審評中心的新藥研究申請(IND)批件，以開展治療慢性阻塞性肺病(COPD)的臨牀試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509668428","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509668428?lang=zh_tw&edition=fundamental","pubTime":"2025-02-05 12:44","pubTimestamp":1738730657,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142.HK)发布公告，集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件，以开展治疗慢性阻塞性肺病(COPD)的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05124447953908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1576","BK1141","TSLP","BK1583","02142","03347","BK1161"],"gpt_icon":0},{"id":"2509697426","title":"和鉑醫藥HBM9378/SKB378治療慢性阻塞性肺疾病的臨牀試驗申請獲中國國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2509697426","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509697426?lang=zh_tw&edition=fundamental","pubTime":"2025-02-05 12:28","pubTimestamp":1738729680,"startTime":"0","endTime":"0","summary":"HBM9378/SKB378旨在通过抑制TSLP介导的信号通路以减轻气道炎症，改善COPD患者的肺功能。作为潜在同类最佳的长效TSLP抗体，HBM9378/SKB378展现出了卓越的生物物理学特性。关于HBM9378/SKB378 HBM9378/SKB378是由和铂医药与科伦博泰联合开发的一款抗体药物，双方共同享有其在大中华区及部分东南亚、西亚国家的权益。目前，和铂医药已在中国完成了HBM9378/SKB378针对中重度哮喘治疗的I期临床试验，针对该适应症的II期临床试验也即将开启。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4612167_ZH12167_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","02142","BK1583","TSLP","BK1161"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TSLP\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"TSLP","amount":0.55,"announcedDate":"2025-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-07","defaultRemindTime":1746624600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-08","payableDate":"2025-05-07","currency":"USD","dateTimestamp":1746590400000,"payDate":"2025-05-08"},{"date":"2025-04-02","symbol":"TSLP","amount":0.55,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-02","defaultRemindTime":1743600600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-02","currency":"USD","dateTimestamp":1743566400000,"payDate":"2025-04-03"},{"date":"2025-03-05","symbol":"TSLP","amount":0.7,"announcedDate":"2025-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-05","defaultRemindTime":1741185000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-06","payableDate":"2025-03-05","currency":"USD","dateTimestamp":1741150800000,"payDate":"2025-03-06"},{"date":"2025-02-05","symbol":"TSLP","amount":1,"announcedDate":"2025-02-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-05","defaultRemindTime":1738765800000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-06","payableDate":"2025-02-05","currency":"USD","dateTimestamp":1738731600000,"payDate":"2025-02-06"},{"date":"2025-01-23","symbol":"TSLP","amount":1.3,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-23","defaultRemindTime":1737642600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-24","payableDate":"2025-01-23","currency":"USD","dateTimestamp":1737608400000,"payDate":"2025-01-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TSLP\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-22","recordDate":"2023-11-24","paymentDate":"2023-11-27","value":0.5775,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-22","value":0.6664,"currency":"USD"},{"executeDate":"2024-01-24","recordDate":"2024-01-25","paymentDate":"2024-01-26","value":0.5555,"currency":"USD"},{"executeDate":"2024-02-21","recordDate":"2024-02-22","paymentDate":"2024-02-23","value":0.313,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-22","value":0.5189,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TSLP\",market:\"US\",delay:false,,,undefined,":{}}}